Ginkgo Bioworks Holdings ROE 2020-2022 | DNA
Current and historical return on equity (ROE) values for Ginkgo Bioworks Holdings (DNA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Ginkgo Bioworks Holdings ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-12-31 |
$-2.11B |
$1.74B |
-132.52% |
| 2022-09-30 |
$-3.53B |
$1.44B |
-228.18% |
| 2022-06-30 |
$-2.96B |
$1.57B |
-186.18% |
| 2022-03-31 |
$-2.35B |
$1.61B |
-195.50% |
| 2021-12-31 |
$-1.83B |
$1.57B |
-229.23% |
| 2021-06-30 |
$-0.15B |
$0.01B |
-6160.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.549B |
$0.478B |
|
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
|
